Study of breast cancer markers after CDK4/6 inhibitor treatment
Part of Cancer, Skin clinical trials.
This study looks at lab markers and clinical features in people with certain types of breast cancer who are being treated with, or have already been treated with a CDK4/6 inhibitor like abemaciclib (ciclib-based therapy). It aims to understand patterns that may help doctors better characterize breast cancer after these treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that is ER-positive and HER2-negative (or HR-positive with node-positive, higher-risk early disease)
- You are currently on, or have been treated with ciclib (a CDK4/6 inhibitor)–based therapy
- You are an adult and you can and will review consent details and sign the study consent form
- You are not pregnant and you are not nursing
- You are willing and able to follow the study’s procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at patients whose breast cancer returns after starting a CDK4/6 inhibitor (like abemaciclib or ribociclib) along with hormone therapy. The goal is to understand why the cancer comes back and find better ways to treat it.
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
This trial compares two types of CDK4/6 inhibitor pills (dalpiciclib vs. abemaciclib or ribociclib) taken after surgery for early-stage, hormone-positive, HER2-negative breast cancer. The goal is to see which is better tolerated and may help lower the risk of the cancer coming back.
This study is looking at how well people stick to a treatment plan that combines hormone therapy with a pill called a CDK4/6 inhibitor after surgery for early-stage breast cancer. The goal is to learn more about adherence so doctors can help patients stay on track.
This study looks at how well a combination of two medicines (a CDK4/6 inhibitor and an aromatase inhibitor) works for people with a certain type of advanced breast cancer. It aims to gather real-world information to better understand treatment patterns and outcomes.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
Hear when a new Anatomic Stage IV Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.